John Oidtman

Head of Global Clinical Operations, EMD Serono

John Oidtman is Head of Global Clinical Operations and is a member of the Global Clinical Development Leadership Team. He is responsible for leading the strategic execution of our Global Clinical Operations, including clinical trial management, clinical quality management, regional clinical operations, clinical data management, clinical applications & innovation, service provider management, clinical operations China & Japan, and clinical trial financial planning and analysis.

John has over 30 years of experience in the global pharmaceutical industry. He has a keen focus on accelerating drug development and strongly believes in fostering a global culture that is reflective of being inclusive and collaborative, which aligns with our culture at Merck. He is deeply committed to the cross-functional global development of his teams and strongly believes in leadership by example. He has initiated a variety of opportunities to lead, introduce and to implement new technologies and work processes into organizations that he has led; scaling great ideas and maintaining a competitive advantage. Prior to joining Merck, he served within Pfizer’s Global Product Development as Vice President of Global Clinical Trial Execution, with end-to-end oversight of over 400 trials conducting in over 40 countries. From 2011 to 2015, he served as VP of Clinical Trial Support and Compliance with responsibilities that ranged from developing a multi-therapeutic site network and ensuring program feasibility, to overseeing protocol conduct and monitoring site quality across the globe. As VP of Clinical Trial Support and Compliance, John led an enterprise-wide transformation of Pfizer’s in-country Clinical Operations to a fully outsourced model. He began his Pfizer career within the legacy Searle Company in 1997 holding various leadership positions in regulatory affairs at Searle, Pharmacia and Pfizer. Prior to his time at Pfizer, John held positions in toxicology, quality assurance and regulatory affairs at Rhone-Poulenc Rorer.